enables marketing of Celacade for the treatment of chronic heart
failure in the 27 member countries of the E.U. Celacade is also the
only CE Mark approved product that specifically targets the
destructive chronic inflammation underlying the development and
progression of heart failure. Under the CE Mark in Europe, Celacade
is approved for the treatment of all NYHA Class II patients and NYHA
Class III, & IV heart failure patients who do not have a history of
prior heart attack. We currently expect that the first clinical sites
in Germany will be in a position to offer Celacade therapy to
patients in April 2008.
Due to the fact that we recently provided a detailed update on corporate activities during our Annual Shareholders' Meeting on March 25, 2008, we will not host a conference call at this time. A replay of the Annual Shareholders' Meeting presentation is available at http://www.vasogen.com.
Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage clinical development for the treatment of chronic heart failure in the United States. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs.
Certain statements containe
|SOURCE Vasogen Inc.|
Copyright©2008 PR Newswire.
All rights reserved